SS
FENC icon

SBI Securities’s Fennec Pharmaceuticals FENC Stock Holding History

SBI Securities’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$9 – 4102
2025
Q3 		$9 Buy
+1
New +$9 ﹤0.01% 4044

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities's FENC Position: Q4 2025 in Review

SBI Securities sold out of Fennec Pharmaceuticals (FENC) in Q4 2025, closing a stake of 1 share — an estimated $9 sold.

SBI Securities first reported a position in FENC in Q3 2025 and held it in 1 quarter. The position peaked at $9 in Q3 2025. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

  • SBI Securities reported no remaining Fennec Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 1 Fennec Pharmaceuticals share in Q4 2025, an estimated $9.
  • SBI Securities first reported a position in Fennec Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • SBI Securities's Fennec Pharmaceuticals position peaked at $9 in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.